Medical Condition News

RSS

Dabigatran as effective as warfarin in preventing subsequent strokes among atrial fibrillation patients

The drug dabigatran was as effective as the currently recommended drug – warfarin – in preventing a subsequent stroke among people with atrial fibrillation and prior stroke or transient ischemic attack – and it did so with less bleeding according to late-breaking science presented at the American Stroke Association's International Stroke Conference 2010.

27 Feb 2010

Cancer researchers assess PCI-32765 drug that targets molecular abnormalities of lymphoma cells

Cancer researchers have high hopes for a new therapy for patients with certain types of lymphoma and leukemia.

27 Feb 2010

Prevention of recurrent strokes: Antiplatelet drug cilostazol effective and safer than aspirin

The antiplatelet drug cilostazol — used in the United States to treat leg pain associated with peripheral vascular disease — was more effective and safer than aspirin at preventing recurrent strokes in a Japanese trial presented as late-breaking science at the American Stroke Association's International Stroke Conference 2010.

27 Feb 2010

Gene signature may help identify risk of colon cancer recurrence

A gene signature, first identified in mouse colon cancer cells, may help identify patients at risk of colon cancer recurrence, according to a recent study by Vanderbilt-Ingram Cancer Center researchers.

26 Feb 2010

Carotid artery stenting and carotid endarterectomy equally safe and effective for people at risk for stroke

Carotid artery stenting, a less invasive alternative to surgery on the carotid artery (carotid endarterectomy), is equally safe and effective for people at risk for stroke as carotid endarterectomy, according to a major new study presented today at the 2010 International Stroke Conference in San Antonio, Texas.

26 Feb 2010

Gaucher disease: FDA approves VPRIV

The U.S. Food and Drug Administration has approved velaglucerase alfa for injection (VPRIV) to treat children and adults with a form of the rare genetic disorder Gaucher disease.

26 Feb 2010

CAMH signs licensing agreement with US-based Athena Diagnostics to market new genetic test

For the second time in as many months the Centre for Addiction and Mental Health has signed a licensing agreement with US-based Athena Diagnostics Inc. to market a new genetic test.

From Thermo Fisher Scientific Inc. 26 Feb 2010

Vion Pharmaceuticals' Onrigin SPA: FDA responds

VION PHARMACEUTICALS, INC. announced today that it had received a response from the U.S. Food and Drug Administration on a Special Protocol Assessment for its oncology therapeutic Onrigin™ (laromustine) Injection.

26 Feb 2010

Arena Pharmaceuticals' lorcaserin NDA: FDA assigns PDUFA date

Arena Pharmaceuticals, Inc. announced today that the US Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) date of October 22, 2010, for the review of the lorcaserin New Drug Application (NDA). The acceptance of the lorcaserin NDA filing confirms that the application is sufficiently complete to permit a substantive review, and the PDUFA date is the goal date for the FDA to complete its review of the NDA.

26 Feb 2010

Notch-blocking drug effective against brain cancer stem cells, but more than one targeted attack needed

Working with mice, Johns Hopkins scientists who tested drugs intended to halt growth of brain cancer stem cells - a small population of cells within tumors that perpetuate cancer growth - conclude that blocking these cells may be somewhat effective, but more than one targeted drug attack may be needed to get the job done.

26 Feb 2010

Widely used biomarkers in early detection of liver cancer are not ideal: Study

Widely used biomarkers are not optimal in early detection of liver cancer, the third most common cause of cancer-related death worldwide, according to a new study published in this month's Gastroenterology.

26 Feb 2010

Larynx preservation using chemotherapy followed by radiation is effective treatment: Study

Head and neck cancer patients receiving induction chemotherapy followed by radiation to preserve their larynx have a low-risk of severe voice disability and almost half experienced no eating or swallowing problems, according to a first of its kind study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM.

26 Feb 2010

UCLA School of Nursing selects CytoCore's PadKit Collection Kit for comparative cytology study of cervical cancer

CytoCore Inc., the developer of cost-effective products used in the practice of cytology for the detection and diagnosis of cancer and cancer related diseases, announced today that PadKit® Collection Kit, a transport kit using an intralabial device for the collection of gynecological samples, has been selected by the UCLA School of Nursing as the sample collection system for a comparative cytology study of cervical cancer.

26 Feb 2010

$Fragility fractures: 'Own the Bone' program for enhancing prevention and treatment$

Fragility fractures: 'Own the Bone' program for enhancing prevention and treatment

As many as half of all women and a quarter of men over the age of 50 can expect to sustain a fractured bone related to osteoporosis or low bone density. To enhance prevention and treatment of these fragility fractures, NewYork-Presbyterian Hospital/Columbia University Medical Center has implemented an innovative program called Own the Bone™ developed by the American Orthopaedic Association.

26 Feb 2010

Prevention of heart attacks: Resveratrol appears to exhibit broader action than aspirin

With the realization that half of the people experiencing a sudden mortal heart attack were taking aspirin on the day of their demise, and the fact that higher-than-recommended doses of aspirin are needed to prevent blood clot formation in coronary arteries, coupled with an announcement that the red wine molecule resveratrol (rez-vair-ah-trawl) may protect from sudden mortal heart attack in a superior fashion to aspirin, suggests re-evaluation of cardiology's current instruction regarding prevention of heart attacks, says Nate Lebowitz MD, cardiologist with the Advanced Cardiology Institute in Ft. Lee, New Jersey.

26 Feb 2010

Genoptix to participate in Aetna's national provider network to offer laboratory and diagnostic services

Genoptix, Inc. today announced that it will participate in Aetna's (AET) national provider network to offer specialized laboratory and comprehensive diagnostic services designed to optimize the care of patients suffering from hematomalignancies, or cancers of the blood and bone marrow, including leukemia and lymphoma.

26 Feb 2010

Integrative oncology program aims to address cancer patients' needs from every angle

The very instant Penny Kukovec was diagnosed with breast cancer her world permanently changed. Suddenly, it felt as if her life was out of her control. She felt powerless and overwhelmed. There were so many unanswered questions.

26 Feb 2010

Researchers develop new technique to reduce acrylamide in French fries

Researchers of Ghent University - department of Food Safety and food Quality developped a technique to to reduce acrylamide in French fries on an industrial scale. Acrylamide is a product that may cause cancer and was discovered in various foods.

26 Feb 2010

Evolving sex disparity in midlife stroke prevalence: Further study needed

When it comes to stroke prevalence, it appears that the gender gap is widening. According to a new report from a researcher at the Keck School of Medicine of the University of Southern California (USC), women between the ages of 35 and 64 are almost three times more likely to have a stroke compared to men in the same age group.

26 Feb 2010

Rapid, multiplexed genotyping method to identify SNPs that affect warfarin dose developed

Researchers from the Ohio State University have developed a rapid, multiplexed genotyping method to identify the single nucleotide polymorphisms (SNPs) that affect warfarin dose. The related report by Yang et al, "Rapid Genotyping of SNPs Influencing Warfarin Drug Response by SELDI-TOF Mass Spectrometry," appears in the March 2010 issue of the Journal of Molecular Diagnostics.

26 Feb 2010

Medical Condition News

Dabigatran as effective as warfarin in preventing subsequent strokes among atrial fibrillation patients

Cancer researchers assess PCI-32765 drug that targets molecular abnormalities of lymphoma cells

Prevention of recurrent strokes: Antiplatelet drug cilostazol effective and safer than aspirin

Gene signature may help identify risk of colon cancer recurrence

Carotid artery stenting and carotid endarterectomy equally safe and effective for people at risk for stroke

Gaucher disease: FDA approves VPRIV

CAMH signs licensing agreement with US-based Athena Diagnostics to market new genetic test

Vion Pharmaceuticals' Onrigin SPA: FDA responds

Arena Pharmaceuticals' lorcaserin NDA: FDA assigns PDUFA date

Notch-blocking drug effective against brain cancer stem cells, but more than one targeted attack needed

Widely used biomarkers in early detection of liver cancer are not ideal: Study

Larynx preservation using chemotherapy followed by radiation is effective treatment: Study

UCLA School of Nursing selects CytoCore's PadKit Collection Kit for comparative cytology study of cervical cancer

Fragility fractures: 'Own the Bone' program for enhancing prevention and treatment

Prevention of heart attacks: Resveratrol appears to exhibit broader action than aspirin

Genoptix to participate in Aetna's national provider network to offer laboratory and diagnostic services

Integrative oncology program aims to address cancer patients' needs from every angle

Researchers develop new technique to reduce acrylamide in French fries

Evolving sex disparity in midlife stroke prevalence: Further study needed

Rapid, multiplexed genotyping method to identify SNPs that affect warfarin dose developed

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Latest News